1. Interferon Alfa Therapy in an Infant with Juvenile Chronic Myelogenous Leukemia
- Author
-
Carlo Tolone, G. Canino, M. D'Avanzo, R Toraldo, F Iafusco, V Pistoia, F Vetrano, Toraldo, Roberto, Vetrano, F, Pistoia, V, Tolone, Carlo, Canino, G, D'Avanzo, M, and Iafusco, F.
- Subjects
Male ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Juvenile chronic myelogenous leukemia ,Alpha (ethology) ,Alpha interferon ,Leukocyte Count ,Antigens, CD ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Internal medicine ,Leukocytes ,medicine ,Humans ,Interferon alfa ,Chemotherapy ,business.industry ,Lymphoblast ,Remission Induction ,Infant ,Interferon-alpha ,Hematology ,Immunotherapy ,Cytokine ,Pediatrics, Perinatology and Child Health ,Immunology ,business ,medicine.drug - Abstract
We describe an infant with juvenile chronic myelogenous leukemia (JCML), the diagnosis of which was made by the characteristic clinical and hematologic findings. The absence of a related HLA-compatible donor for bone marrow transplantation coupled with the awareness that chemotherapy is usually ineffective prompted our decision to treat the patient with lymphoblastoid interferon-alpha [alpha(Ly)-IFN]. During the 26-month course of treatment with alpha(Ly)-IFN an incomplete regression of hematologic and clinical findings was achieved. The above results, along with the easy administration and absence of considerable side effects, suggest that alpha(Ly)-IFN may be a useful therapeutic tool in patients affected by JCML awaiting bone marrow transplantation.
- Published
- 1995
- Full Text
- View/download PDF